Table 1.

Summary of preclinical efficacy studies with EFNA4-ADC

PF-06647263
Tumor subtypePDXaStandard of care Regression (TTP, days) or % TGIEFNA4 protein (ng/mg)Dose level (mg/kg)Regression (TTP, days) or % TGI
TNBC: BasalBR544% TGI1.80.036Regression (32)
0.09Regression (53)
0.27Regression (215)
BR2227% TGI1.910.018No activity
0.03621% TGI
0.0955% TGI
0.27Regression (43)
BR3130% TGI1.020.09Regression (56)
0.27Regression (91)
BR5649% TGI1.010.018No activity
0.03634% TGI
0.0956% TGI
0.27Regression (60)
TNBC: Normal-likeBR1316% TGI1.000.018No activity
0.03636% TGI
0.09Regression (42)
0.27Regression (84)
TNBC: Unknown144580ND1.740.0311% TGI
0.155% TGI
0.3Regression (53)
TNBC: CLBR25No activity0.470.2727% TGI
BR64No activity0.660.27No activity
BR: HER2+BR1766% TGIND0.27No activity
OV: HGSOV39Regression (28)ND0.036No activity
0.0945% TGI
0.27Regression (49)
OV44Regression (60)1.390.03653% TGI
0.0959% TGI
0.27Regression (53)
OV6335% TGI0.490.036No activity
0.0959% TGI
0.27Regression (88)
OV: MMMTOV45Regression (20)3.640.018No activity
0.03670% TGI
0.09Regression (60)
0.27Regression (200)
OV55NA0.420.018No activity
0.03667% TGI
0.09Regression (42)
0.27Regression (76)
OV124NAND0.27Regression (152)

Abbreviations: NL, normal-like; ND, no data.

  • aBreast SOC = 1.5 mg/kg doxorubicin q7dx2; Ovarian-HGS SOC = 5 mg/kg cisplatin q7dx2; Ovarian MMMT SOC = 35 mg/kg irinotecan q4dx3.